Annual CFF
$194.62 M
+$77.69 M+66.44%
December 31, 2024
Summary
- As of March 13, 2025, URGN annual cash flow from financing activities is $194.62 million, with the most recent change of +$77.69 million (+66.44%) on December 31, 2024.
- During the last 3 years, URGN annual CFF has risen by +$122.30 million (+169.11%).
- URGN annual CFF is now at all-time high.
Performance
URGN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$71.00 K
-$39.53 M-99.82%
December 31, 2024
Summary
- As of March 13, 2025, URGN quarterly cash flow from financing activities is $71.00 thousand, with the most recent change of -$39.53 million (-99.82%) on December 31, 2024.
- Over the past year, URGN quarterly CFF has dropped by -$39.53 million (-99.82%).
- URGN quarterly CFF is now -99.96% below its all-time high of $163.51 million, reached on March 31, 2019.
Performance
URGN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$194.62 M
+$31.00 K+0.02%
December 31, 2024
Summary
- As of March 13, 2025, URGN TTM cash flow from financing activities is $194.62 million, with the most recent change of +$31.00 thousand (+0.02%) on December 31, 2024.
- Over the past year, URGN TTM CFF has increased by +$31.00 thousand (+0.02%).
- URGN TTM CFF is now -28.20% below its all-time high of $271.06 million, reached on June 30, 2024.
Performance
URGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
URGN Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +66.4% | -99.8% | +0.0% |
3 y3 years | +169.1% | +321.9% | +169.1% |
5 y5 years | +17.8% | -71.0% | +17.8% |
URGN Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +169.1% | -99.9% | +192.2% | -28.2% | +619.1% |
5 y | 5-year | at high | +1077.6% | -99.9% | +142.3% | -28.2% | >+9999.0% |
alltime | all time | at high | >+9999.0% | -100.0% | +117.8% | -28.2% | >+9999.0% |
UroGen Pharma Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | $194.62 M(+66.4%) | $71.00 K(-99.8%) | $194.62 M(+0.0%) |
Sep 2024 | - | $39.61 M(-60.5%) | $194.59 M(-28.2%) |
Jun 2024 | - | $100.28 M(+83.5%) | $271.06 M(+58.6%) |
Mar 2024 | - | $54.66 M(>+9900.0%) | $170.92 M(+46.2%) |
Dec 2023 | $116.93 M(+20.4%) | $40.00 K(-100.0%) | $116.93 M(-17.8%) |
Sep 2023 | - | $116.08 M(>+9900.0%) | $142.26 M(+421.4%) |
Jun 2023 | - | $143.00 K(-78.7%) | $27.28 M(+0.8%) |
Mar 2023 | - | $671.00 K(-97.4%) | $27.06 M(-72.1%) |
Dec 2022 | $97.13 M(+34.3%) | $25.37 M(+2204.1%) | $97.13 M(+35.4%) |
Sep 2022 | - | $1.10 M(-1529.9%) | $71.73 M(+1.8%) |
Jun 2022 | - | -$77.00 K(-100.1%) | $70.47 M(-50.7%) |
Mar 2022 | - | $70.74 M(<-9900.0%) | $143.06 M(+97.8%) |
Dec 2021 | $72.32 M(+337.6%) | -$32.00 K(-81.0%) | $72.32 M(-0.2%) |
Sep 2021 | - | -$168.00 K(-100.2%) | $72.43 M(-0.3%) |
Jun 2021 | - | $72.52 M(>+9900.0%) | $72.66 M(+341.9%) |
Mar 2021 | - | $4000.00(-94.9%) | $16.44 M(-0.5%) |
Dec 2020 | $16.53 M | $78.00 K(+27.9%) | $16.53 M(-1.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2020 | - | $61.00 K(-99.6%) | $16.69 M(-6.0%) |
Jun 2020 | - | $16.30 M(>+9900.0%) | $17.76 M(+868.3%) |
Mar 2020 | - | $90.00 K(-63.3%) | $1.83 M(-98.9%) |
Dec 2019 | $165.25 M(+148.8%) | $245.00 K(-78.2%) | $165.25 M(-1.2%) |
Sep 2019 | - | $1.13 M(+201.9%) | $167.21 M(+0.7%) |
Jun 2019 | - | $373.00 K(-99.8%) | $166.06 M(+0.2%) |
Mar 2019 | - | $163.51 M(+7332.1%) | $165.67 M(+149.4%) |
Dec 2018 | $66.42 M(+7.9%) | $2.20 M(<-9900.0%) | $66.42 M(+3.5%) |
Sep 2018 | - | -$14.00 K(-33.3%) | $64.17 M(+0.6%) |
Jun 2018 | - | -$21.00 K(-100.0%) | $63.78 M(-49.4%) |
Mar 2018 | - | $64.26 M(<-9900.0%) | $125.95 M(+104.5%) |
Dec 2017 | $61.59 M(<-9900.0%) | -$56.00 K(-86.0%) | $61.59 M(-0.1%) |
Sep 2017 | - | -$399.00 K(-100.6%) | $61.64 M(-0.6%) |
Jun 2017 | - | $62.15 M(<-9900.0%) | $62.04 M(<-9900.0%) |
Mar 2017 | - | -$108.00 K | -$108.00 K |
Dec 2016 | -$9000.00(-100.0%) | - | - |
Dec 2015 | $21.58 M | - | - |
FAQ
- What is UroGen Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for UroGen Pharma?
- What is UroGen Pharma annual CFF year-on-year change?
- What is UroGen Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for UroGen Pharma?
- What is UroGen Pharma quarterly CFF year-on-year change?
- What is UroGen Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for UroGen Pharma?
- What is UroGen Pharma TTM CFF year-on-year change?
What is UroGen Pharma annual cash flow from financing activities?
The current annual CFF of URGN is $194.62 M
What is the all time high annual CFF for UroGen Pharma?
UroGen Pharma all-time high annual cash flow from financing activities is $194.62 M
What is UroGen Pharma annual CFF year-on-year change?
Over the past year, URGN annual cash flow from financing activities has changed by +$77.69 M (+66.44%)
What is UroGen Pharma quarterly cash flow from financing activities?
The current quarterly CFF of URGN is $71.00 K
What is the all time high quarterly CFF for UroGen Pharma?
UroGen Pharma all-time high quarterly cash flow from financing activities is $163.51 M
What is UroGen Pharma quarterly CFF year-on-year change?
Over the past year, URGN quarterly cash flow from financing activities has changed by -$39.53 M (-99.82%)
What is UroGen Pharma TTM cash flow from financing activities?
The current TTM CFF of URGN is $194.62 M
What is the all time high TTM CFF for UroGen Pharma?
UroGen Pharma all-time high TTM cash flow from financing activities is $271.06 M
What is UroGen Pharma TTM CFF year-on-year change?
Over the past year, URGN TTM cash flow from financing activities has changed by +$31.00 K (+0.02%)